Instil Bio (TIL) Receivables - Accured (2024 - 2026)

Instil Bio has reported Receivables - Accured for 3 years, with the latest figure at $8.3 million in Q2 2026.

• On a quarterly basis, Receivables - Accured changed N/A year-over-year to $8.3 million in Q2 2026; TTM through Jun 2026 was $8.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $7.7 million, up 79.07% from the prior year.
• Receivables - Accured was $8.3 million for Q2 2026 at Instil Bio, up from $8.0 million in the prior quarter.
• The five-year high for Receivables - Accured was $8.3 million in Q2 2026, with the low at $4.3 million in Q4 2024.
• Average Receivables - Accured over 3 years is $7.1 million, with a median of $7.7 million recorded in 2025.
• The largest YoY upside for Receivables - Accured was 79.07% in 2025 against a maximum downside of 79.07% in 2025.
• Over 3 years, Receivables - Accured stood at $4.3 million in 2024, then jumped by 79.07% to $7.7 million in 2025, then climbed by 7.79% to $8.3 million in 2026.
• The last three Receivables - Accured figures came in at $8.3 million (Q2 2026), $8.0 million (Q1 2026), and $7.7 million (Q4 2025), per Business Quant data.